{"id":"rivaroxaban-aspirin","safety":{"commonSideEffects":[{"rate":"null","effect":"Gastrointestinal bleeding"},{"rate":"null","effect":"Hemorrhage"},{"rate":"null","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rivaroxaban works by directly inhibiting Factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots. Aspirin, on the other hand, inhibits platelet aggregation by irreversibly inhibiting the enzyme cyclooxygenase-1 (COX-1), which is necessary for the production of thromboxane A2, a potent platelet activator.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that prevents blood clot formation, while aspirin inhibits platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:26.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis and pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT05009862","phase":"PHASE4","title":"The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-19","conditions":"Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT05198960","phase":"PHASE3","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2022-07-13","conditions":"Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis","enrollment":1308},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT05047172","phase":"PHASE3","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-08-02","conditions":"Intracranial Arteriosclerosis, Stroke","enrollment":1683},{"nctId":"NCT06901466","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-06-13","conditions":"Mitral Regurgitation","enrollment":880},{"nctId":"NCT04990791","phase":"PHASE4","title":"WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2021-08-26","conditions":"Coronary Syndrome","enrollment":48},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT02810704","phase":"PHASE4","title":"Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-12","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":18883},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT02168829","phase":"PHASE4","title":"Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2016-01","conditions":"Atrial Fibrillation, Stroke","enrollment":1284},{"nctId":"NCT07195812","phase":"PHASE4","title":"Rivaroxaban for Slow Coronary Flow After PCI in STEMI","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10","conditions":"ST Elevation Myocardial Infarction, No-Reflow Phenomenon","enrollment":60},{"nctId":"NCT04694248","phase":"NA","title":"Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-03","conditions":"Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction","enrollment":172},{"nctId":"NCT05907629","phase":"","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-06-24","conditions":"Stroke, Intracranial Atherosclerotic Stenosis (ICAS)","enrollment":300},{"nctId":"NCT06580223","phase":"PHASE3","title":"Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-09-01","conditions":"Multiple Myeloma, Venous Thromboembolism","enrollment":530},{"nctId":"NCT06444178","phase":"PHASE1","title":"Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-30","conditions":"Healthy Volunteers","enrollment":224},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT05622500","phase":"NA","title":"Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2022-09-03","conditions":"Chronic Venous Insufficiency, Chronic Venous Thrombosis, Iliac Vein Stenosis","enrollment":12},{"nctId":"NCT02387229","phase":"PHASE3","title":"Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF","status":"TERMINATED","sponsor":"Montreal Heart Institute","startDate":"2015-03","conditions":"ATRIAL FIBRILLATION","enrollment":1238},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT06986369","phase":"PHASE4","title":"Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2021-05-04","conditions":"Atherosclerosis, Coronary","enrollment":140},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT02846532","phase":"PHASE3","title":"Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-11-16","conditions":"Thrombosis","enrollment":112},{"nctId":"NCT06715007","phase":"","title":"Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-20","conditions":"Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity","enrollment":300},{"nctId":"NCT06873321","phase":"PHASE4","title":"VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization","status":"RECRUITING","sponsor":"Science Valley Research Institute","startDate":"2024-02-24","conditions":"Peripheral Arterial Disease, Venous Thormboembolism, Cardiovascular Diseases","enrollment":100},{"nctId":"NCT05353140","phase":"NA","title":"LAAO Versus NOAC in Patients with AF and PCI","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":1386},{"nctId":"NCT05775965","phase":"PHASE2","title":"HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-05-21","conditions":"Hip Fractures","enrollment":250},{"nctId":"NCT05797376","phase":"PHASE4","title":"Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2021-08-24","conditions":"Atherosclerosis of Artery, Coronary Artery Disease, Peripheral Arterial Disease","enrollment":92},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT04853719","phase":"PHASE4","title":"Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients","status":"COMPLETED","sponsor":"Science Valley Research Institute","startDate":"2021-04-20","conditions":"Peripheral Artery Disease, Intermittent Claudication","enrollment":88},{"nctId":"NCT02735902","phase":"PHASE4","title":"Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-06-01","conditions":"Transcatheter Aortic Valve Replacement","enrollment":170},{"nctId":"NCT05077683","phase":"PHASE3","title":"Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10-10","conditions":"Myocardial Infarction, Acute, Left Ventricular Thrombus","enrollment":560},{"nctId":"NCT06486792","phase":"PHASE4","title":"Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09-01","conditions":"Stroke, Ischemic Stroke, Cerebral Infarction","enrollment":1148},{"nctId":"NCT04298567","phase":"","title":"Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-02-25","conditions":"Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD)","enrollment":300},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT04128956","phase":"PHASE2","title":"Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2020-03-11","conditions":"Venous Thromboses, Stent Stenosis","enrollment":172},{"nctId":"NCT03428373","phase":"PHASE2, PHASE3","title":"Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-01-17","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II","enrollment":57},{"nctId":"NCT05750758","phase":"NA","title":"Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty","status":"COMPLETED","sponsor":"Henan Institute of Cardiovascular Epidemiology","startDate":"2023-02-20","conditions":"Acute Coronary Syndrome","enrollment":140},{"nctId":"NCT06239415","phase":"","title":"PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy (PRO-PAS)","status":"UNKNOWN","sponsor":"Istituti Clinici Scientifici Maugeri SpA","startDate":"2022-03-31","conditions":"Peripheral Atherosclerotic Disease","enrollment":250},{"nctId":"NCT04075240","phase":"PHASE3","title":"VTE Prevention Following Total Hip and Knee Arthroplasty","status":"RECRUITING","sponsor":"Sudeep Shivakumar","startDate":"2021-02-04","conditions":"Venous Thromboembolism","enrollment":5400},{"nctId":"NCT05638867","phase":"PHASE4","title":"NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-25","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":3944},{"nctId":"NCT04925219","phase":"NA","title":"REmotely Supervised Exercise Therapy Trial 2","status":"UNKNOWN","sponsor":"Mid and South Essex NHS Foundation Trust","startDate":"2021-06-01","conditions":"Claudication, Intermittent, Peripheral Arterial Disease","enrollment":40},{"nctId":"NCT04324463","phase":"PHASE3","title":"Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2020-04-21","conditions":"Coronavirus, Severe Acute Respiratory Syndrome","enrollment":6667},{"nctId":"NCT05700266","phase":"PHASE2, PHASE3","title":"Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-30","conditions":"Ischemic Stroke, Intracranial Atherosclerosis, Stenosis","enrollment":1180},{"nctId":"NCT02164578","phase":"PHASE3","title":"Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2015-04","conditions":"Type 2 Diabetic Patients","enrollment":179},{"nctId":"NCT04401761","phase":"","title":"A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-05-28","conditions":"Coronary Artery Disease, Peripheral Artery Disease","enrollment":3189},{"nctId":"NCT04273516","phase":"PHASE2, PHASE3","title":"Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2020-08-22","conditions":"Stroke, Prevention","enrollment":42},{"nctId":"NCT04753372","phase":"","title":"Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk","status":"COMPLETED","sponsor":"Maatschap Cardiologie Zwolle","startDate":"2020-12-21","conditions":"Coronary Artery Disease (CAD), Peripheral Arterial Disease (PAD)","enrollment":645},{"nctId":"NCT04142125","phase":"PHASE3","title":"Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2020-02-03","conditions":"Ischemic Stroke, Intracranial Atherosclerotic Disease","enrollment":101},{"nctId":"NCT06019741","phase":"PHASE4","title":"Rivaroxaban Post Coronary Bypass Surgery","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2021-02-01","conditions":"Post Coronary Bypass Surgery Patients","enrollment":234},{"nctId":"NCT05960721","phase":"NA","title":"Low-dose NOAC Versus GDMT After LAAO","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-07-06","conditions":"Atrial Fibrillation","enrollment":4220},{"nctId":"NCT03764241","phase":"PHASE3","title":"Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-02-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":280},{"nctId":"NCT05546957","phase":"NA","title":"Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-05","conditions":"Healthy Volunteer","enrollment":60},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT05705089","phase":"PHASE3","title":"Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI","status":"COMPLETED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2020-07-30","conditions":"Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction","enrollment":50},{"nctId":"NCT05744804","phase":"NA","title":"Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-03-01","conditions":"Patient With Anterior Myocardial Infarction","enrollment":150},{"nctId":"NCT05718531","phase":"PHASE3","title":"Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-02-01","conditions":"Coronary Artery Ectasia","enrollment":200},{"nctId":"NCT04333407","phase":"NA","title":"Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2020-04-03","conditions":"COVID-19","enrollment":320},{"nctId":"NCT05546320","phase":"PHASE4","title":"Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-10-15","conditions":"Patent Foramen Ovale, Migraine","enrollment":1000},{"nctId":"NCT05671276","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Occlusion, Silent Cerebral Embolism","enrollment":150},{"nctId":"NCT05644210","phase":"","title":"Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-10-01","conditions":"Antiphospholipid Syndrome","enrollment":80},{"nctId":"NCT01776424","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-28","conditions":"Prevention & Control","enrollment":27395},{"nctId":"NCT04135677","phase":"PHASE4","title":"Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-11-11","conditions":"Left Atrial Appendage Thrombosis, Thrombi, Stroke","enrollment":826},{"nctId":"NCT05035277","phase":"PHASE3","title":"AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-12-04","conditions":"Aortic Stenosis","enrollment":360},{"nctId":"NCT05573958","phase":"PHASE4","title":"To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Sarmad Zahoor","startDate":"2022-10-01","conditions":"Acute Coronary Syndrome","enrollment":90},{"nctId":"NCT02832544","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-08-22","conditions":"Rheumatic Heart Disease","enrollment":4565},{"nctId":"NCT05515120","phase":"PHASE2, PHASE3","title":"Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2021-01-03","conditions":"Venous Thromboembolism, Anticoagulant-induced Bleeding, Venous Thromboses","enrollment":58},{"nctId":"NCT02666742","phase":"PHASE4","title":"DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation","status":"COMPLETED","sponsor":"Kansas City Heart Rhythm Institute","startDate":"2017-02-16","conditions":"Ventricular Tachycardia, Premature Ventricular Contraction, Stroke","enrollment":246},{"nctId":"NCT03942913","phase":"","title":"Prospective Real-world Registry Describing Treatment Regimens","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-10-10","conditions":"Subject Under Anticoagulant","enrollment":573},{"nctId":"NCT05308030","phase":"EARLY_PHASE1","title":"Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-08-01","conditions":"Peripheral Arterial Disease","enrollment":100},{"nctId":"NCT02832531","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority","status":"WITHDRAWN","sponsor":"Population Health Research Institute","startDate":"2022-01","conditions":"Rheumatic Heart Disease","enrollment":""},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT04994223","phase":"EARLY_PHASE1","title":"Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease","status":"UNKNOWN","sponsor":"Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi","startDate":"2021-07-02","conditions":"Combined Anticoagulation and Antithrombotic Therapy, PAD - Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT03746275","phase":"","title":"Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-11-13","conditions":"Atherosclerosis","enrollment":5798},{"nctId":"NCT04619927","phase":"PHASE4","title":"Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-03-01","conditions":"Peripheral Arterial Disease","enrollment":2276},{"nctId":"NCT05210725","phase":"PHASE4","title":"Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-03-01","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT05233124","phase":"PHASE2","title":"Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2021-09-01","conditions":"Acute Coronary Syndrome, Coronary Artery Ectasia","enrollment":60},{"nctId":"NCT04218656","phase":"PHASE4","title":"DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-06-08","conditions":"Peripheral Artery Disease","enrollment":159},{"nctId":"NCT03273322","phase":"PHASE2, PHASE3","title":"Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-09-13","conditions":"Atrial Fibrillation, Atrial Appendage, Hemorrhage","enrollment":105},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT04805710","phase":"PHASE4","title":"Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI","status":"UNKNOWN","sponsor":"Shenyang Northern Hospital","startDate":"2021-03-17","conditions":"Rivaroxaban","enrollment":1020},{"nctId":"NCT04305028","phase":"","title":"Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD","status":"UNKNOWN","sponsor":"Poznan University of Medical Sciences","startDate":"2021-03-10","conditions":"Peripheral Arterial Disease","enrollment":100},{"nctId":"NCT02504216","phase":"PHASE3","title":"Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-18","conditions":"Peripheral Artery Disease","enrollment":6564},{"nctId":"NCT04059679","phase":"PHASE4","title":"Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy","status":"UNKNOWN","sponsor":"LifeBridge Health","startDate":"2020-01-30","conditions":"Coronary Artery Disease, Peripheral Artery Disease","enrollment":30},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT04256525","phase":"PHASE4","title":"Prophylactic Anticoagulation for Catheter-related Thrombosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Venous Thrombosis Due to Central Venous Access Device (Disorder), Prophylactic Anticoagulation, Patients With Tumor","enrollment":1640},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02998905","phase":"PHASE2","title":"NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2017-04-26","conditions":"Atrial Fibrillation, Intracerebral Hemorrhage","enrollment":30},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT04031859","phase":"PHASE2","title":"Risk Stratification Procedure for Thromboembolism Prophylaxis","status":"COMPLETED","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2018-10-10","conditions":"Total Knee Replacement Surgeries","enrollment":242}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xarelto"],"phase":"phase_3","status":"active","brandName":"Rivaroxaban + Aspirin","genericName":"Rivaroxaban + Aspirin","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a small molecule inhibitor of coagulation factor X, classified as an INHIBITOR. It is being studied in combination with aspirin for the efficacy and safety in patients with anterior myocardial infarction, among other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}